Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
Study Achieves Primary Endpoint, Demonstrating Statistically Significant Reductions in Liver Fat from Baseline to Week 12 in Patients Receiving VK2809 as...
Prnewswire Viking Therapeutics Inc Ligand Pharmaceuticals Incorporated Therapeutics Inc Study Achieves Primary Endpoint Liver Fat Patients Receiving
Source: prnewswire.com